A Phase 2 interventional study of PTG-300 in β-thalassemia, Ineffective Erythropoiesis and Chronic Anemia, sponsored by Protagonist Therapeutics, Inc.. Completed at 33 sites in 9 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-07-16.
Sponsored by Protagonist Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Thalassemia with a site in Turkey — 2 open to participants now, 5 under way, 3 of them phase 3. Thalassemia · Turkey.
Among the 20 studies in Thalassemia with a site in Turkey, this one is the 13th largest by enrollment, is one of 2 that started in 2018, is one of 8 in phase 2, and was the 12th registered.
250 studies on the registry are indexed under Thalassemia; 43 are open to participants now.
Browse Thalassemia studies →2 of the 20 studies in Thalassemia with a site in Turkey are open now. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Turkey, United States, Canada and 14 more countries
Ages 2+
Agios Pharmaceuticals, Inc. · Sites in Turkey, Belgium, Brazil and 5 more countries
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 28 Thalassemia studies recruiting now, 7 (25%) set no upper age limit and 18 (64%) stop at 75 or younger; 22 take children under 18; none take healthy volunteers.
This study: 12 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is above the median of 33 across 170 interventional studies indexed under Thalassemia.
Median enrollment 128 across the 20 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 20 have an industry lead sponsor. The 10 most frequent:
Protagonist Therapeutics, Inc. is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 1 (11%) have results posted.
Protagonist Therapeutics, Inc. has 2 studies filed under Thalassemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Thalassemia with a site in Turkey, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2 open-label, single-arm design study with dose escalation by subject cohort . The study is designed to monitor the PTG-300 safety profile, to obtain preliminary evidence of efficacy of PTG-300 for the treatment in β-thalassemia.
This is a Phase 2 open-label, single-arm design study with dose escalation by subject cohort and with the potential for individual titration (dose increase or decrease) within each cohort. The study is designed to monitor the PTG-300 safety profile, to obtain preliminary evidence of efficacy of PTG-300 for the treatment of chronic anemia in β-thalassemia and to evaluate the appropriate dosing regimen for PTG-300 in the target population
250 studies on the registry are indexed under Thalassemia; 43 are open to participants now.
This study's enrollment of 63 is above the median of 33 across 170 interventional studies indexed under Thalassemia.
Browse Thalassemia studies →Protagonist Therapeutics, Inc. is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 1 (11%) have results posted.
Compared within Thalassemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Main Inclusion Criteria:
Inclusion criteria applicable only for NTD β-thalassemia subjects:
Inclusion criteria applicable only for TD β-thalassemia subjects:
Main Exclusion Criteria:
History within 6 months of screening of any of the following:
myocardial infarction, unstable angina, , decompensated heart failure requiring hospitalization, congestive heart failure ( Class 3 or 4), uncontrolled arrhythmias, cardiac revascularization, stroke, uncontrolled hypertension (resting systolic blood pressure [BP] > 160mmHg or resting diastolic BP > 100mmHg on more than one occasion) or uncontrolled diabetes (Hgb A1c > 9% or > one episode of severe hypoglycemia).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PTG-300 Subcutaneous
Drug: PTG-300
Subcutaneous (SC)
NTD: Proportion of responders at each dose
NTD subjects who achieve an increase in Hgb without transfusion
Time frame: 4 week period
TD: Proportion of clinical responders at each dose
TD subjects who achieve a reduction in red blood cell (RBC) units required over an 8 week period
Time frame: 8 week period
Ran from Dec 2018 to primary completion in Jul 2020, 19 months.
Of 25 phase 2 interventional studies under Thalassemia, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 67. This study's 19 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rusfertide
Protagonist Therapeutics, Inc.